UPDATE 1-Anthem selects Gilead as primary supplier of hepatitis C drugs
January 08, 2015 at 17:45 PM EST
Jan 8 (Reuters) - Health insurer Anthem Inc on Thursday said it reached a deal under which Gilead Sciences Inc's hepatitis C drug Harvoni will be the primary treatment for patients infected with the most common strain of the liver-destroying virus.